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The sympathetic division of the autonomic nervous system
comprises cell types as diverse as sympathetic neurons, which
control internal organs and blood vessels via noradrenergic
nerve terminals, the endocrine, catecholamine-releasing chro-
maffin cells, and the chemoreceptive type I cells of the carotid
body, which serve as peripheral oxygen sensors. While sympa-
thetic neurons form the para- and prevertebral ganglia, chromaf-
fin cells are situated in the adrenal medulla or in paraganglia
located in close proximity to large blood vessels, along sympa-
thetic nerves innervating pelvic organs and within sympathetic
ganglia during development. Paraganglionic cells also include
the type I cells of the carotid body, which originate from
sympathetic progenitors of the superior cervical ganglion during
embryonic development (Kameda 2014).
The fascination of these so-called sympathoadrenal (SA) cells
lies not only in their multiple vital functions but also in their
intriguing pathobiology with a variety of benign and malignant
tumors originating from them. Neuroblastoma is the most com-
mon extra-cranial solid tumor of childhood. This neoplasm is
associated with the developing sympathetic nervous system or
the developing adrenal medulla. In contrast, pheochromocytoma
and paraganglioma usually occur in adults. By definition, pheo-
chromocytomas originate from the adrenal medulla, while
paragangliomas are derived from extra-adrenal chromaffin tissue
or chemoreceptive paraganglia (Lloyd et al. 2017).
How the distinct individual properties and functions of SA
cells are related to their susceptibility to tumor formation and
their tumor biology is one of the central points addressed in
this special issue. Neuroblastoma, as a tumor derived from
developing tissue, has been in particular associated with dys-
function or mutations of molecules that regulate SA cell de-
velopment (Chan et al. 2018), including MYCN, ALK
(Janoueix-Lerosey et al. 2018), and PHOX2B (Trochet et al.
2004; Mossé et al. 2004). Some pheochromocytomas and
paragangliomas have been intimately linked to hypoxic path-
way genes, including hypoxia-inducible transcription factors
(HIFs) and the von Hippel-Lindau tumor suppressor (VHL)
(Fliedner et al. 2018; Kluckova and Tennant 2018). This may
at least in part be related to the fact that oxygen sensing is an
integral part of the normal physiology of type I carotid body
cells as well as early chromaffin cells (Nurse et al. 2018).
Hypoxic pathway genes are important for the proper function
of oxygen sensing and the plasticity of these cells (Prabhakar
and Semenza 2016; Nurse et al. 2018). These molecules, in
particular HIF-2α, in addition have putative functions during
the early development of SA cells (Brown et al. 2009), linking
them also to neuroblastoma (Påhlman and Mohlin 2018). The
recent discovery that sympathetic neurons and adrenal chro-
maffin cells are derived from separate progenitors with dis-
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the original concept of a common SA progenitor, will be of
high value for the understanding of the pathogenesis of neu-
roblastoma as well as pheochromocytoma. It also raises new
questions as to the cellular origin of neuroblastoma (see Chan
et al. (2018) and the BNeuroblastoma^ section) and to the
developmental origin of type I cells of the carotid body.
This special issue covers the pathobiology of SA cells, with
a focus on tumor biology. Reviews range from very basic to
clinically orientated research aiming to understand the patho-
genesis of these diseases, to identify appropriate diagnosis and
therapy strategies, and to determine the individual prognosis. In
an effort to link pathobiology to regular cell function, this spe-
cial issue also deals with selected aspects of the normal biology
of SA cells. It includes a review providing a comprehensive
picture on the development of the diverse types of SA cells
(Chan et al. 2018), a section covering neuroblastoma from de-
velopment and animal models up to its clinical features, a part
on pheochromocytomas and paragangliomas, and a section on
the role and pathology of oxygen sensing pathways in the ca-
rotid body and chromaffin cells. This special issue aims to
bridge the gap between fundamental and clinical science, to
identify similarities and differences between the distinct types
of tumors originating from SA cells, and to foster new ideas for
the benefit of both fundamental science and patients.
Neuroblastoma
In this part of the special issue, current knowledge on neuro-
blastoma is delineated from clinical presentation, genetic pre-
disposition, tumor development, and animal models to major
tumor driver genes, intratumor heterogeneity, and relapse.
Neuroblastoma patients are stratified into various catego-
ries including low-risk patients with survival rates greater than
90% and aggressive, high-risk neuroblastoma with current
overall survival rates below 50%. Risk stratification is impor-
tant to avoid overtreatment of low-risk patients resulting in
late complications and to select and improve targeted thera-
pies for high-risk patients. Clinical presentation, diagnosis,
risk stratification according to the INRG staging, and therapy
are reviewed by Tolbert andMatthay (2018). Notably, targeted
small molecule inhibitors and immunotherapy are presently
used for relapsed and refractory patients but may be included
in the personalized initial therapy of newly diagnosed patients.
Current research aims to understand the mechanisms that
underlie tumor initiation, growth, and relapse using different
animal models where tumors can be induced by the expression
of single or combinations of potential tumor driver genes iden-
tified in high-throughput genetic analysis. However, as about
two thirds of neuroblastoma tumors are devoid of obvious del-
eterious mutations, the search also continues for other mecha-
nisms of tumor initiation, e.g., perturbations of epigenetic
mechanisms controlling sympathoadrenal development that
may lead to genomic instabilities and subsequently to
chromosomal alterations. Thus, the detailed description of the
normal development of sympathoadrenal cells by Chan et al.
(2018) provides an essential reference point for studies on ab-
errant development during neuroblastoma development. The
classical scheme of normal sympathoadrenal development has
been recently changed by single-cell RNAseq and cell lineage
analysis demonstrating that sympathetic neurons and chromaf-
fin cells have a different cellular origin, deriving directly from
neural crest cells and Schwann cell progenitor cells (SCPs),
respectively (Furlan et al. 2017). These findings implicate
SCPs, besides neural crest progenitor cells and sympathetic
neuroblasts, as potential cell of origin for neuroblastoma.
Neuroblastoma induction by transgenic expression of a tu-
mor driver gene in noradrenergic cells was first shown in the
mouse for MYCN, followed by activated Alk and Lin28B
(reviewed by Tsubota and Kadomatsu (2018)). As their expres-
sion was controlled by the Th or Dbh promotor, noradrenergic
neuroblasts were thus identified as cell of origin, at least in these
models. However, as the MYCN-transfected neural crest cell
line JoMa-1 and MYCN-transfected primary neural crest cells
generate neuroblastoma upon subcutaneous injection in mice,
neural crest cells may also represent cells of origin for human
neuroblastoma (discussed by Janoueix-Lerosey et al. (2018) and
Tsubota and Kadomatsu (2018)). Both mouse and zebrafish
have been used to confirm the neuroblastoma driver function
of gene amplifications (MYCN) or somatic mutations
(ALKF1174L) and to define molecular mechanisms underlying
tumor development. This included evidence for cooperative in-
teractions between MYCN and ALKF1174L or MYCN and
PTPN11 resulting in strongly increased tumor penetrance.
Tumor models were also used for pharmacological screens lead-
ing to the identification of novel drugs (reviewed by Casey and
Stewart (2018)). As pointed out by Casey and Stewart (2018),
the zebrafish model may be superior to that of the mouse for
studying TERT- and ATRX-dependent mechanisms of telomere
lengthening that are potential drivers in a large proportion of
human high-risk neuroblastoma (Peifer et al. 2015; Valentijn
et al. 2015). Mouse telomeres are much longer and Tert mutants
in mice are viable in contrast to mutations affecting telomere
maintenance in human and zebrafish. Thus, although key onco-
genic pathways are conserved between human, mouse, and
zebrafish, the specific advantages and disadvantages of the
models (e.g., the gene duplications in zebrafish) should be taken
into consideration depending on the question analyzed.
Whereas transgenic animal models have been essential for
the analysis of specific oncogene functions, patient-derived xe-
nografts (PDX) display features that are very close to human
neuroblastoma with respect to molecular and cellular
characteristics, including invasive behaviors. Braekeveldt and
Bexell (2018) discuss methodology, advantages, and limitations
of neuroblastoma PDX, highlighting also the usefulness of PDX








The recent discovery that neuroblastoma cell lines display
either a noradrenergic, a neural crest-like/mesenchymal, or a
mixed identity and that most primary tumors are composed of
a mixture of noradrenergic and neural crest-like/mesenchymal
neuroblastoma cells (Boeva et al. 2017; van Groningen et al.
2017) raises the question whether neural crest-like/mesenchy-
mal cells may represent neuroblastoma cancer stem cells.
Putative neuroblastoma cancer stem cells have been identified
based on marker gene expression, increased ability for tumor
formation, chemoresistance, and formation of metastases
(reviewed by Tomolonis et al. (2018)). Of particular interest
are highly tumorigenic CD114-positive cells that express neu-
ral crest cell and EMT markers and are present as a minor
population in all neuroblastoma cell lines and primary neuro-
blastoma samples analyzed. However, additional in vivo anal-
ysis by serial re-implantation experiments is required to see
whether these are transformed stem cells that self-renew, dif-
ferentiate into diverse progenies, and drive continuous tumor
growth (Kreso and Dick 2014). Intratumoral heterogeneity
has also been inferred from the sequential acquisition of so-
matic mutations during tumor progression and is supported by
the finding that pre-existing clones of cells with activated
RAS/MAPK and MYCN expand in relapsed neuroblastoma
(Schulte et al. 2018). As emphasized by these authors, the
existence of diverse populations of cancer cell clones that
respond differentially to therapy represents a major challenge
for treatment design in personalized treatment. Påhlman and
Mohlin (2018) point out that hypoxia-inducible factor (HIF)-
2α, which is transiently expressed in sympathetic neuroblasts
during their early normal development, is a marker of a certain
population of Bstem cell-like^ neuroblastoma cells in the
perivascular niche and associated with aggressive disease.
They suggest that HIF-2 represents a possible therapeutic tar-
get for the treatment of neuroblastoma proposing a strategy
that involves the induction of differentiation of immature HIF-
2α-positive tumor cells by inhibiting HIF-2.
Spontaneous regression is observed in many types of tu-
mors but it is most prevalent in neuroblastoma. The fourfold
increase in neuroblastoma prevalence observed in mass
screenings implicates that 75% of tumors detected will regress
subsequently. Interestingly, spontaneously regressing tumors
are characterized by specific molecular traits, which correlated
with good prognosis and allowed the classification as MS
tumors (4S in the old nomenclature). As detailed by Brodeur
(2018), high-level expression of TrkA, low telomerase, and
epigenetic and immunological properties of 4S tumors indi-
cate potential mechanisms involved in tumor regression and
how to enhance this process in patients.
Genetic determinants that predispose to neuroblastoma have
been first identified in familial forms of the disease with muta-
tions in ALKobserved in 75% and PHOX2Bmutations in about
15% of cases. In contrast, very few recurrent somatic mutations
are present in sporadic neuroblastoma, in contrast to many adult
cancers with disease-defining somatic mutations driving tumor
development. However, many common susceptibility alleles
were discovered by genome-wide association studies that are
associated with neuroblastoma development and progression.
The enrichment of some of these variants in low- or high-risk
tumors implicates specific effects of defined genotypes on neu-
roblastoma phenotypes. As reviewed by Ritenour et al. (2018),
these studies identified genes with oncogenic or tumor suppres-
sive roles, including CASC15, NBAT-1, BARD1, LMO1,
HACE1, and LIN28B. Interestingly, a number of rare germline
variants (e.g., TP53, BARD1, BRCA1, BRCA2) that may have
a higher effect size were recently discovered by extensive whole
genome and exon sequencing of neuroblastoma patients. The
identification of CASC15 and NBAT-1 long non-coding RNAs
in neuroblastoma development illustrates the importance of epi-
genetic regulation in neuroblastoma development. As detailed in
this issue by Durinck and Speleman (2018), epigenetic mecha-
nisms generally play important roles in cancer, with about 20%
of mutations in pediatric cancers observed in epigenetic regula-
tors involved in DNA methylation, histone modification, and
chromatin remodeling. Characteristic traits of the neuroblastoma
epigenome are linked to specific neuroblastoma subtypes,
allowing improved tumor diagnosis and providing novel ap-
proaches for therapeutic intervention.
After its discovery as predominant driver of familial neu-
roblastoma, ALK turned out to be also the most frequently
somatically mutated gene in sporadic neuroblastoma. As ty-
rosine kinase receptor, it represented a promising therapeutic
target and small molecule inhibitors were rapidly translated to
clinical trials. The present state of our understanding of ALK
function in normal development of sympathoadrenal cells as
well as in neuroblastoma initiation, synergistic interactions
between activated ALK and MYCN, and current progress in
approaches to pharmacologically interfere with tumor growth
is covered by Janoueix-Lerosey et al. (2018).
Pheochromocytoma and Paraganglioma
In contrast to neuroblastomas, which typically arise in infancy
or very early childhood and result from somatic mutations of
developmentally regulated genes, the pathogenesis of pheo-
chromocytoma and paraganglioma is more complex. At least
40% are hereditary, and the causative mutations are largely
distinct from those associated with neuroblastoma. Although
a few pheochromocytomas and paragangliomas, particularly
hereditary cases, present in young children, most occur in
adults. There are also marked genotype-phenotype correla-
tions that segregate the tumors into distinct Bclusters^ differ-
ing in predominant tumor location, catecholamine production,









Most basic research on pheochromocytomas and
paragangliomas begins in the context of genotype-phenotype
clusters (reviewed by Fishbein and Wilkerson (2018)). Two
major clusters were initially described through transcriptional
profiling of hereditary tumors (Dahia et al. 2005). BCluster 1,^
characterized by hypoxic signaling pathways, initially
consisted of tumors with mutations of VHL and of genes
encoding subunits of succinate dehydrogenase, collectively re-
ferred to as SDHx genes. BCluster 2^ is characterized by kinase
signaling pathways and initially consisted of tumors with mu-
tations of RET and NF1. Somatic mutations of some of the
same genes, especially NF1, RET, and VHL but not SDHx
genes, are now frequently recognized in sporadic as well as in
hereditary pheochromocytomas and paragangliomas. NF1mu-
tations, the most common, are reported in 20–30% of sporadic
cases. The clusters have also been expanded by discovery of
new hereditary susceptibility genes and new somatic mutations
not usually associated with hereditary susceptibility. The latter
include occasional mutations ofHRAS and ATRX. Tumors with
germline or somatic mutations are assigned to clusters accord-
ing to the overall match of their transcription signatures.
However, these signatures are not always equivalent to those
of VHL, NF1, or RET, and sub-clustering has been proposed.
Mutation of TMEM127, which encodes a protein involved in
intracellular protein trafficking, is included in cluster 2 but is
not associated with RAS activation. MAX, which encodes a
protein that heterodimerizes with and antagonizes transcrip-
tional effects ofMYC protein, is also in cluster 2.Within cluster
1, there are marked differences between tumors harboring VHL
mutations and those with mutations of genes encoding subunits
of succinate dehydrogenase (Fliedner et al. 2018). The former
usually involve the adrenal and are benign, while the latter are
usually extra-adrenal, often are multiple, and often metastasize,
especially those tumors with SDHBmutations. A new group of
aggressive tumors characterized by Wnt signaling pathways
was described in The Cancer Genome Atlas (TCGA) publica-
tion in 2017 (Fishbein et al. 2017).
The relationships between genotype, tumor location, and
catecholamine production in pheochromocytomas and
paragangliomas pose conundrums from a developmental
perspective. In normal SA tissues, epinephrine is produced
almost exclusively in the adrenal gland, while other paraganglia
produce norepinephrine and/or dopamine. This largely holds true
for the corresponding tumors, except that adrenal tumors with
VHL or SDHx mutations are usually noradrenergic. In addition,
quantitative differences in production of catecholamines and do-
pamine are associated with different genotypes. Possible expla-
nations for these associations are analyzed by Fliedner et al.
(2018) who suggest that different innate sensitivities of develop-
ing chromaffin cell populations to hypoxia might exacerbate vul-
nerability to mutations that alter hypoxic signaling pathways and
by Fishbein and Wilkerson (2018), who emphasize the primary
influences of genotype.
From a clinical perspective, tumors with SDHx mutations
are perhaps of greatest interest because they have been esti-
mated to comprise up to 80% of familial aggregates of pheo-
chromocytomas and paragangliomas and almost 40% of tu-
mors that metastasize (Pasini and Stratakis 2009). The dual
metabolic functions of SDH as TCA cycle intermediate and as
complex ll in the mitochondrial electron transport chain sug-
gest several hypothetical metabolic drivers of tumor develop-
ment and potential therapeutic targets (reviewed by Kluckova
and Tennant (2018)). First, accumulation of succinate may
inhibit 2-OG-dependent dioxygenases that use 2-OG as a
co-substrate and generate succinate as a byproduct. These in-
clude prolyl hydroxylase domain (PHD) enzymes that hy-
droxylate hypoxia-inducible transcription factors (HIFs) in
the presence of oxygen, thereby tagging them for
ubiquitination and degradation, and DNA hydroxylases that
demethylate genomic DNA. The result is that SDH-deficient
tumors show both pseudohypoxic signaling mediated by
downstream targets of HIFs, and a Bhypermethylator^ pheno-
type that may inactivate tumor suppressor genes by promoter
methylation. A second, more controversial, contributor to the
pathogenesis of SDH-deficient tumors is overproduction of
reactive oxygen species (ROS), which is postulated to result
from reverse electron transport from an over-reduced ubiqui-
none pool between complex I/II and complex III. While ROS
have been proposed to function as hypoxic signaling mole-
cules in these tumors, the evidence reviewed by Kluckova and
Tennant is inconclusive. Further, although DNA damage by
ROS is thought to drive genome instability and increase mu-
tation load in other types of tumors, pheochromocytomas and
paragangliomas are known to have an extraordinarily low
mutation load (Fishbein and Wilkerson 2018).
A difficulty in studies of pheochromocytoma and
paraganglioma is the paucity of experimental models
(Lepoutre-Lussey et al. 2018). In contrast to neuroblastomas,
for which there aremultiple human cell lines andmousemodels,
there are no human pheochromocytoma or paraganglioma cell
lines, and rodent models for these tumors exist only for suscep-
tibility genes in cluster 2. The latter includes the PC12 rat pheo-
chromocytoma cell line (Max mutation) (Greene and Tischler
1976),MPCmouse pheochromocytoma cell line (Nf1mutation)
(Powers et al. 2000), and a transgenic MEN2B mouse charac-
terized by pheochromocytomas and malformed adrenal glands
fused with sympathetic ganglia (Ret mutation) (Smith-Hicks
et al. 2000). The inability to develop human cell lines results
at least in part from the intrinsically low growth rate of pheo-
chromocytomas and paragangliomas, which can take years for a
single doubling in vivo. However, the absence of rodent models
for cluster 1 tumors, particularly those with SDHBmutations, is
perplexing. Although several types of genetically engineered
mice have been generated to address this problem, none have
developed pheochromocytomas or paragangliomas. One im-








allele usually occurs as a large deletion in chromosome 1p that
probably also includes tumor suppressor genes. Chromosome
1p deletions are also associated with neuroblastomas and sever-
al other types of tumor.
Although there is much still to be learned about the devel-
opmental basis for differences between pheochromocytomas
and paragangliomas in different locations and with different
genotypes, clinical medicine has effectively utilized existing
knowledge of the physiological characteristics of these tumors
to develop new modalities of imaging and treatment. Taïeb
and Pacak (2018) review current molecular imaging and
theranostic approaches, which are largely based on phenotype
and genotype correlations. Molecular imaging, also known as
functional imaging, serves multiple purposes. These include
discrimination of pheochromocytoma or paraganglioma from
other types of masses identified by anatomic imaging (e.g.,
CAT scan or MRI), screening for multiple tumors and metas-
tases, and detection of molecular targets for therapy. The last
of these, detection of therapeutic targets, is the basis for
theranostic imaging, which utilizes radiolabeled tracer mole-
cules to identify tumor characteristics such as transporters or
receptors that can later be targeted using the same tracers
tagged with more destructive radioisotopes.
Three main attributes of pheochromocytoma and
paraganglioma influence the choice of molecular imaging mo-
dality: catecholamine metabolism, somatostatin receptor ex-
pression, and glucose metabolism. Imaging focused on cate-
cholamine metabolism exploits norepinephrine transporter,
vesicular monoamine transporters, or amino acid transporters
to concentrate tracer into tumor cells. The most widely utilized
tracer is metaiodobenzylguanidine (MIBG), which is taken up
by the norepinephrine transporter. Imaging is usually per-
formed with MIBG tagged with 123I, predominantly a gamma
ray emitter. For tumor ablation, the radionuclide is 131I, a
strong beta particle emitter. MIBG is optimal for imaging
and treatment of relatively well-differentiated tumors that pro-
duce abundant catecholamines, best exemplified by pheochro-
mocytomas. However, it has also been useful in management
of patients with neuroblastomas, especially for imaging (Park
et al. 2017; Pfluger and Piccardo 2017). Methods have been
proposed to increase the therapeutic efficacy of 131I-MIBG in
poorly differentiated tumors by upregulating norepinephrine
transporter, in some cases using agents that might mimic nor-
mal developmental regulation (Martiniova et al. 2011).
Somatostatin receptor imaging is best suited to
paragangliomas, especially those with SDHx mutations and
those in the head and neck. The latter are often TH-negative
but strongly express somatostatin receptors. Since approxi-
mately 1994, tumors with somatostatin receptors have been
imaged using the OctreoScan, a patented scintigraphic tech-
nique using the ligand 111In-DPTA-D-Phe-1-octreotide and
providing a two-dimensional image (Maxwell and Howe
2015). Over the past decade, new radioligands and three-
dimensional detection technology such as positron emission
tomography (PET)/computed tomography (CT) have greatly
increased the sensitivity of this imaging modality. A current
approach employs the positron emitter 68Ga linked to 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and
any of several somatostatin analogs, e.g., 68Ga-DOTATATE,
68Ga-DOTATOC, and 68Ga-DOTANOC. In these constructs,
the DOTA compound is a chelator that links the radioisotope
to the peptide ligand. For tumor ablation (peptide radioreceptor
therapy, PRRT), 68Ga is replaced with 177Lu, a short-range
beta emitter, or 90Y, a long-range beta emitter.
Imaging focused on glucose metabolism is not specific
for pheochromocytomas and paragangliomas and is uti-
lized for many types of tumors. The most commonly used
tracer is the positron emitter 18F-fluorodeoxyglucose (18F-
FDG). As discussed by Taïeb and Pacak (2018), 18FFDG
PET has been particularly valuable in localizing SDHx-
related tumors, especially those with metastases, but
might soon be supplanted by somatostatin receptor imag-
ing. The sensitivity of this modality for tumors with SDHx
mutations might result in part from upregulation of glu-
cose transporters, which are downstream targets of
hypoxia-inducible transcription factors, in pseudohypoxic
tumors (Baumann et al. 2007).
Oxygen sensing and its pathology
in the carotid body and chromaffin cells
In contrast to the chromaffin cells of the adrenal medulla, the
type I (or glomus) cells of the carotid body and similar struc-
tures located along the branches of the vagus nerve (e.g., aortic
bodies) are negligible in their contribution to circulating cate-
cholamines but rather serve a sensory function and utilize their
transmitters to excite sensory nerve fibers and for paracrine
regulatorymechanisms. The carotid body is the primary sensor
of peripheral arterial pO2 that drives enhanced ventilation in
the setting of lowered oxygen tension without concomitant
increase in pCO2, as is in the case of high altitude. This oxygen
sensor function was originally proposed by the Spanish histol-
ogist Fernando de Castro as early as 1928 and was confirmed
soon after that by the Belgian physiologists Jean-Francois
Heymans and Corneille Heymans (father and son), resulting
in awarding the Nobel Prize in Physiology or Medicine to
Corneille Heymans in 1938 (de Castro 2009). Even beyond
the end of that century, however, the molecular mechanisms of
oxygen sensing in the carotid body remained unclear. Many,
often complimentary but also contradictory hypotheses, have
been posed and tested, but consensus was not reached. Indeed,
the Novartis Foundation Symposium Signalling Pathways in
Acute Oxygen Sensing, held in London in 2005, was opened by
the chair, Michael Duchen, by stating: BThis field has been








and failure to reach consensus among researchers.^ (Duchen
2006). On this background, it is a fundamental breakthrough to
tackle the unique properties of the carotid body by an unbiased
approach at expression level. Comparing the transcriptome of
the carotid body (oxygen sensor) and the adult adrenal medulla
(closely related but not a professional oxygen sensor) unex-
pectedly revealed a selective high expression of a member of
the olfactory receptor family, olfr78, which proved to represent
a G-protein-coupled short-chain fatty acid receptor monitoring
lactate accumulation in the carotid body (Chang et al. 2015). In
this issue, Zhou and Matsunami (2018) comprehensively sum-
marize the most recent developments in this line of research,
extending transcriptome analysis to single-cell level. This ap-
proach corroborated the finding of overrepresentation of
olfr78, but also added new players into the game, i.e., the
atypical subunits of the mitochondrial electron transport chain
Ndufa4l2 andCox4i2 (Zhou et al. 2016; Gao et al. 2017). Zhou
andMatsunami (2018) also point towards the enormous poten-
tial of this approach, if put on a larger scale, in distinguishing
novel cell types, an issue being debated for a long time (e.g.,
type A and type B glomus cells in the rat carotid body,
McDonald and Mitchell (1975)), but likewise never reaching
consensus.
At the next higher structural organization level, Jose Lopez-
Barneo steps in and brings together what expression of atyp-
ical mitochondrial electron transport chain subunits of com-
plex IV might mean for production of reactive oxygen species
(ROS) further upstream in the transport chain, and how this
might finally translate into activation of sensory nerve fibers
through what he calls Bchemosensory synapses^ (López-
Barneo 2018). This review broadens the view upon the carotid
body in that not only excitation of sensory nerve fibers and
respiratory reflexes are considered as responses to hypoxia,
but also signaling through Bchemo-proliferative synapses^ to
adjacent stem cells which represent a population of the glial-
like type II (or sustentacular) cells that partially enwrap type I
cells. In chronic hypoxemia, these cells expand, giving rise to
both type I and type II cells and resulting in gross hypertrophy
of the carotid body that can even be measured by weighing of
carotid bodies obtained at autopsy (Smith et al. 1982). Lopez-
Barneo’s group was the first to discover this stem cell niche in
the carotid body (Pardal et al. 2007), which nicely correlates
with the just recently identified origin of adrenal chromaffin
cells from Schwann cell progenitors (Furlan et al. 2017).
This proliferative response seen in chronic hypoxia is not so
evident when there is chronic, repeated exposure to acute epi-
sodes of hypoxia, a condition termed Bintermittent hypoxia^
(Pawar et al. 2008; Welch et al. 2017). Patients experience
intermittent hypoxia in sleep apnea, a disease characterized by
periodic cessation of breathing during sleep. These patients
exhibit heightened cardiovascular sympathetic activity and hy-
pertension, and activation of the carotid body chemoreflex is
considered as themajor driver of these autonomic abnormalities
(Prabhakar 2016). In this issue, Nanduri Prabhakar
focusses upon the initial mechanisms within the carotid
body leading to this abnormal activation (Prabhakar et al.
2018). As in acute oxygen sensing, ROS are involved, but
they are not exclusively derived from the mitochondrial
respiratory chain and are not the only gaseous messengers
operating in this scenario. Activities of pro-oxidant en-
zymes are upregulated through HIF-dependent pathways
and anti-oxidant enzymes are downregulated. The in-
depth review covers the complex interplay between elevat-
ed ROS and the gaseous messenger carbon monoxide (CO)
and hydrogen sulfide (H2S) (Prabhakar et al. 2018).
Like the type I cells of the carotid body adrenal chromaffin
cells can physiologically respond to acute hypoxia, but primar-
ily during early development. As reviewed by Nurse et al.
(2018), hypoxia triggers catecholamine release in perinatal
chromaffin cells, when the innervation of the adrenal medulla
is not yet functional. Adrenal chromaffin cells downregulate
their sensitivity to acute hypoxia in parallel to splanchnic nerve
innervation, but they can gradually regain it after denervation.
Nurse et al. (2018) discuss the mechanism of hypoxia-triggered
catecholamine release by chromaffin cells, its regulation by
splanchnic nerve innervation, and the plasticity of chromaffin
cells following chronic and intermittent hypoxia. While the
precise mechanism of acute oxygen sensing is still unclear
and controversially discussed, a recent study by Gao et al.
(2017) provided novel insight into putative markers of oxygen
sensitivity by comparing the transcriptome of SA cells with
different sensitivities to oxygen (carotid body type I cells
+++, adult chromaffin cells +, neurons of the superior cervical
ganglion −). The authors highlight a gene expression signature
putatively linked to oxygen sensing, which is shared by carotid
body type I cells and chromaffin cells. It is in particular char-
acterized by elevated levels of HIF-2α, pyruvate carboxylase,
and the atypical mitochondrial electron transport subunits
Ndufa4l2, Cox4i2, and Cox8b. From a pathobiological point
of view, this characteristic molecular profile might be closely
associated with the vulnerability of these cells with regard to the
occurrence of cluster I (pseudohypoxic) pheochromocytoma/
paraganglioma. The molecular players, mechanisms, and the
plasticity of oxygen sensing are furthermore of high relevance
in the context of clinical conditions such as obstructive lung
disease, sleep apnea, and hypertension.
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